Better Performance Faster Treatment Planning Stronger Immune System

BETTER. FASTER. STRONGER.

Better Therapies Faster Diagnosis Stronger Hearts

2017 Research Report Health innovation at UHN Research Snapshot

TOTAL RESEARCHERS 1,094 Appointed Researchers 464 Clinical Researchers 630

RESEARCH SPACE 969,913 sq. ft.

TOTAL FUNDING $386,192,252

TOTAL TRAINEES 783 Fellows 309 Graduate Students 474

TOTAL STAFF 2,098 Institute Staff 1,802 Research Support Staff 296

PUBLICATIONS 3,732

The cover features six UHN researchers whose work exemplifies how we are making health care better, faster and stronger. They are, from top left (clockwise): Drs. Karen Davis, Thomas Purdie, Pamela Ohashi, Michael Laflamme, Frank Rudzicz and Cristina Nostro.

University Health Network (UHN) is a research hospital affiliated with the University of Toronto and a member of the Toronto Academic Health Science Network (TAHSN). UHN comprises the Michener Institute for Education at UHN and four hospitals: the Princess Margaret Cancer Centre (PM Cancer Centre), Toronto General Hospital (TGH), Toronto Rehab (TR) and Toronto Western Hospital (TWH). It has five research institutes: Krembil Research Institute (Krembil), PM Cancer Centre, Techna Institute for the Advancement of Technology for Health (Techna), Toronto General Hospital Research Institute (TGHRI) and Toronto Rehabilitation Institute (TRI). The scope of research and complexity of cases at UHN have made it a national and international source for discovery, education and patient care. BETTER. FASTER. STRONGER.

Welcome Message: Pushing the Limits 2 Featured Research

Why Some Gain When Under Pain 4 More flexible communication in the brain could make pain less of a distraction while performing a task

Making Every Move Count 6 Research exposes a hidden defence mechanism that protects cancer from the body’s immune system

Reading Between the Lines 8 New artificial intelligence platform can diagnose and monitor Alzheimer disease using verbal descriptions of an image

On Target for Cell Therapy 10 New method could lead to safer stem cell-derived diabetes treatments

Artificial Intelligence Feeds Need for Speed 12 Technology is being used to fast-track radiation therapy plans and conserve clinical resources

From Building Blocks to BlueRock 14 BlueRock Therapeutics receives historic investment to advance stem cell research

Support: New funding spurs world-class innovation 16

Discovery: A selection of top research findings 18

Impact: How research at UHN is improving health care 20

UHN Foundations 22

Research Distinctions 26 Research Institutes 28 Research Committees 40 External Sponsors 43 Financials 47 Research Trustee and Advisory Boards 48 Welcome Message Pushing the Limits

High-performance athletes train for years to Emerging technologies have enabled other

become the best in their field. They consistently researchers to improve care at an increasingly

push themselves beyond what they are capable faster pace. These technologies include of, honing their skills through an unwavering advanced DNA sequencing approaches that drive. And once they’ve attained their goal—be reveal the complexities of the human genome it breaking a personal best, winning a gold with unprecedented speed. Our researchers medal or shattering a world record—it’s on to are also developing machine learning methods the next challenge. to reduce the time it takes to plan treatments, so that patients get the care they need The same can be said of our researchers. sooner. Both examples demonstrate how our researchers are using these technologies to their Our researchers tirelessly work to better fullest potential to accelerate the application understand disease, improve the delivery of of research, the delivery of quality care and to care, and the effectiveness and efficiency of ease the burden on the health care system by the health care system. Along with clinicians, reducing wait times. health care professionals, funders and patients,

they make a united front to define the most Others still are building stronger systems. important unmet needs. And together they Our researchers are experts in regenerative work to address these needs while setting and approaches to repair damaged organs, and achieving goals that are far beyond what would leaders in developing rehabilitation programs be possible as individuals. to strengthen patients’ minds and bodies as they age or recover from life-threatening Some of our researchers set their sights on situations. Some are translating their work by

creating a better understanding of disease as commercializing new products or founding new a path towards improved health. Examples companies through history-making investments include those who reveal new molecular targets from private sector partners; these deliverables that lead to the development of better, more fortify the bioeconomy and reinforce the specific therapeutic drugs; those who identify profile of Toronto’s research ecosystem on the gaps in care that inform new, more effective world stage. Regardless of the means, those clinical tools and policies; and those who find engaged in these activities strive to build robust better ways to bring basic research findings to systems—from cells, tissues and organs to the clinic to help patients. This knowledge can networks, consortia and companies—towards be translated into a better approach to doing enriching human health and wellbeing. something, whether it’s a research method, therapeutic strategy or way of performing We hope you will enjoy the examples we surgery. These solutions continually enhance selected in this year’s report to highlight how and refine the delivery of health care. our researchers are helping to make health care better, faster and stronger.

2 Dr. Charlie Chan, Interim President and Chief Dr. Brad Wouters, Executive Vice Dr. Peter Pisters, Past President Executive Officer; Executive Vice President, Clinical President, Science and Research. and Chief Executive Officer. Programs, Quality and Safety; Chief Medical Officer. Why Some Gain When Under Pain More flexible communication in the brain could make pain less of a distraction while performing a task

Despite being hampered by painful injuries, many The researchers focused their study on the activity athletes continue to compete and win. For example, of brain cells in two networks: the executive control Toronto Maple Leafs defenceman Bobby Baun (EC) network and the salience network. The EC played several playoff games with a broken ankle network helps to optimize a person’s behaviour in and helped his team win the Stanley Cup in 1964. response to what’s happening around them; whereas, the salience network is normally engaged when Why is it that some individuals can perform a task— something like pain draws your attention. and do it well—while experiencing pain? Through their analysis, Dr. Davis and her research “There is a complex relationship between pain and team discovered a link between spontaneous brain attention, where pain can modulate attention and activity and task performance with pain. The vice versa. Moreover, the interplay between these synchrony of activity between the EC network and two factors differs from one person to the next,” the salience network, as well as within the salience explains Dr. Karen Davis. network, was more flexible in A-type individuals than P-type individuals. These findings suggest that Dr. Davis has shown that individuals can be brain communication is more flexible in A-type classified as one of two types depending on how individuals—a feature that could be important for

pain affects their performance in doing a task. In prioritizing task performance over pain, producing

P-type individuals, pain impedes their ability to better performance. perform a task; whereas, in A-type individuals, like Bobby Baun, pain enhances their performance. Regarding her future work, Dr. Davis says, “We’d like to explore whether communication flexibility To gain a better understanding of the brain is disrupted in chronic pain and how it is altered mechanisms that contribute to this divergent by treatments for chronic pain—including behaviour during pain, Dr. Davis and her PhD surgery, medications and cognitive-behavioural student Joshua Cheng led a study examining therapy. This will improve our understanding of patterns of brain activity in these two groups. the mechanisms underpinning chronic pain, which will be instrumental for developing more effective First, 51 healthy participants were classified as either and personalized therapies for this debilitating A-type or P-type based on their performance in a condition.” complex mental task in the presence and absence of a painful stimulus. Next, the participants underwent Cheng JC et al. Neuroimage. 2017 Aug 15;157:61-68. Supported a functional MRI (fMRI) scan, while they were not by the Canadian Institutes of Health Research and the Toronto thinking of anything in particular, to measure their General & Western Hospital Foundation. spontaneous brain activity.

4 “When I play hockey, my mind is so focused on the game and scoring a goal that I don’t feel my recurring back and knee pain,” confides Dr. Davis, an avid hockey player and Leafs fan.

Images: (panel on left) Dr. Davis is pictured in her hockey gear; (on this page) the battle that takes place in the brain between pain and attention is illustrated by two hockey players facing off. Making Every Move Count Research exposes a hidden defence mechanism that protects cancer from the body’s immune system

The best defence is a good offence. This adage, often “By looking at tumour biology from this different applied to sports or military strategies, suggests perspective, we have a better understanding of the that attacking one’s opponent offers the greatest barriers that prevent a strong immune response,” protection. Researchers and clinicians are taking explains Dr. Ohashi. “Our research reveals a this approach to fight cancer—developing powerful promising new strategy to develop combined new therapies that seek out and kill cancer cells. therapies that simultaneously target ILCregs while

promoting TIL growth and function—delivering a

One such approach is immune therapy: it works stronger ‘one-two punch’ against the disease.” by boosting the number and activity of tumour- infiltrating lymphocytes (TILs), immune cells that Building on these findings, her team is now go on the offensive by migrating into tumours to developing a test to identify ILCregs in patients, target and destroy them. Although this strategy which may help predict whether the patient will holds promise, challenges remain because certain respond to immune therapy. Dr. Ohashi says, “This tumours have developed defence mechanisms that knowledge would help doctors and patients make block TIL activity. more informed medical decisions, personalize cancer treatment and ultimately improve the These tumours, however, are no match for Dr. effectiveness of immune therapies.” Pamela Ohashi. She is a pioneer in figuring out how the immune system interacts with cancer in Immune therapies order to develop new immune therapies. work by helping the In an article published in the prestigious journal Nature Medicine, Dr. Ohashi and her research team immune system to revealed that an internal battle may be going on: they found that certain ovarian tumours contain target and kill cancer. other immune cells, called regulatory innate lymphoid cells (ILCregs), that block the activity Crome SQ, et al. Nat Med. 2017 Mar;23(3):368-375. Supported of cancer-fighting TILs. The ILCregs did this in by the Canadian Institutes of Health Research, the Cancer two ways: they reduced the ability of TILs to grow Research Institute/Irvington Institute, the Canada Foundation for Innovation, the Ontario Ministry of Research, Innovation and multiply, and altered the ability of the TILs to and Science, the Alexander von Humboldt Foundation, the attack cancer cells. German Research Council, the National Institutes of Health, the Parker Institute for Cancer Immunotherapy and The Princess The team also found that the tumours from some Margaret Cancer Foundation. P Ohashi is a Tier 1 Canada patients contained ILCregs, while those from others Research Chair in Autoimmunity and Tumour Immunity. did not, suggesting that some tumours may be able Image: (opposite page) just as a chess player uses offensive and to attract or promote growth of ILCregs. defensive strategies to win, Dr. Ohashi is finding ways to weaken cancer’s defences while boosting the body’s immune system. 6

Reading Between the Lines New artificial intelligence platform can diagnose and monitor Alzheimer disease using verbal descriptions of an image

How you speak says a lot about you. A hurried For each audio sample, 370 features of speech were voice can show that you are in a rush, while the examined, such as vocabulary richness, vowel tone of your voice can reveal emotion and mood. articulation and pauses between words. Next, the researchers used this data to teach an AI algorithm How you speak can also uncover deeper truths: it how to identify Alzheimer disease. The resulting can provide insight into your mental health. For speech-based diagnostic program was able to example, speech can be used to diagnose aphasia, a detect the disease with an accuracy of more than disorder caused by brain damage that compromises 80%. Not only is the new program just as accurate

an individual’s ability to speak, write or understand as traditional assessment methods, but it is faster , language. cheaper and more sensitive.

“While speech analysis represents a powerful Dr. Rudzicz incorporated these findings into a approach to diagnose certain disorders, this method set of assessment tools that can detect a variety of typically relies on tedious ‘paper-and-pencil’ tests disorders including aphasia and types of dementia. that are time consuming and costly to administer This platform can also be used to monitor disease and interpret,” says Dr. Frank Rudzicz. progression and the effectiveness of new treatments.

To address the shortcomings of traditional speech- To bring this technology to market, Dr. Rudzicz based tests, Dr. Rudzicz’s team has combined subtle co-founded the spin-off company WinterLight differences in speech patterns with the power of Labs. The result: an online app that is accessible artificial intelligence (AI) to create a clinical tool and easy to use. From the comfort of their own that can quickly diagnose Alzheimer disease. home, patients can upload a short voice recording describing what they see in an image—such as a Alzheimer disease progressively damages the brain, picture taken during a camping trip. Within seconds, impairing memory. Although memory loss is the the speech sample is analyzed to generate a set most definitive symptom, speech may be a more of scores describing speech deficits and mental sensitive indicator of brain function: not only do function, which are then interpreted by clinicians. speech deficits appear early in the disease, but they also worsen as it progresses. WinterLight’s app offers a healthier future: one day your phone may be able to notify you at the earliest As a first step toward developing the new clinical sign of disease so that preventative therapies could tool, the research team identified the most prevalent be started to help you stay healthy and active. speech deficits in Alzheimer disease. They did this by analyzing brief speech samples from 264 Fraser KC, et al. J Alzheimers Dis. 2016;49(2):407-22. Supported participants (167 with Alzheimer disease and 97 by the Natural Sciences and Engineering Research Council of without). Canada, the Alzheimer’s Association, the Alzheimer Society of Canada, the National Institutes of Health and Toronto Rehab Foundation. 8

“WinterLight’s platform could help doctors make accurate diagnoses faster.” Images: (panel on left) Dr. Frank Rudzicz; (on this page) within seconds, the WinterLight platform can analyze over 400 features in recorded speech samples to assess a person’s mental function. To learn more, please visit the WinterLight Labs website: http://www.winterlightlabs.com/ On Target for Cell Therapy New method could lead to safer stem cell-derived diabetes treatments

Looking at things from a different angle can often daughter stem cells (pancreatic progenitors) that lead to new and better solutions. That’s because then develop into insulin-producing beta cells. a fresh perspective can help to inspire creativity, innovative thinking and collaboration. Unfortunately, the technique also produces progenitors that mature into cells that do not It’s also why Dr. Cristina Nostro and her team produce insulin. The problem: these contaminating recently embarked on a new collaborative project progenitors need to be removed before the to solve a particularly difficult research problem: therapeutic insulin-producing cells can be safely how to reliably isolate a specific pancreatic cell type used in the clinic. capable of improving current treatments for type I diabetes. Dr. Nostro teamed up with Dr. Thomas Kislinger to explore an entirely new approach to solving this Type I diabetes is a chronic condition in which problem. Together they identified specific proteins cells in the pancreas—known as beta cells—are that are found on the surface of the pancreatic destroyed so little to no insulin is produced. progenitors. They then used one of the proteins— Without insulin, the body is unable to keep known as Glycoprotein 2—to isolate the pancreatic blood sugar levels within a healthy range. When progenitors and remove the contaminating cells. blood sugar levels remain consistently high for a This allowed them to not only control the number prolonged period of time, serious conditions can but also the purity of the newly generated insulin- develop, including heart disease, vision loss, kidney producing cells. disease and nerve damage. “Our long-term goal is to cure type I diabetes using Transplanting healthy beta cells into the pancreas transplants of insulin-producing cells, so it is crucial can restore insulin production and decrease the to have cells that are safe and pure,” explains Dr. number of insulin injections needed to maintain Nostro. “The technique we’ve developed provides normal sugar levels. However, widespread use of a better , more reliable method for generating large this treatment is hampered by a limited supply of quantities of these cells for use in the clinic.” donor beta cells for transplantation. Cogger KF, et al. Nat Comm. 2017 Aug 24;8(1):331. Supported by Using stem cells, Dr. Nostro has addressed this the McEwen Centre for Regenerative Medicine and the Toronto issue by developing a reproducible method for General & Western Hospital Foundation, the Banting and Best Diabetes Centre, the Canadian Institutes of Health Research, the generating large numbers of cells that can safely give Ontario Ministry of Health and Long-Term Care, the National rise to insulin-producing beta cells. The technique, Institutes of Health, the Juvenile Diabetes Research Foundation, which mimics what occurs during pancreas the US Department of Veterans Affairs and the Vanderbilt development, forces stem cells to mature into Diabetes Research and Training Center.

10 “This new approach will help us to develop safer stem cell therapies for diabetes.” In their quest to improve stem cell-derived diabetes treatments, Dr. Nostro (pictured) and her team developed an approach to reliably target and isolate insulin-producing beta cells (depicted as fluorescently labelled green and blue cells). Images: (panel on left) Dr. Frank Rudzicz; (on this page) within seconds, the WinterLight platform can analyze over 400 features in recorded speech samples to assess a person’s mental function. To learn more, please visit the WinterLight Labs website: http://www.winterlightlabs.com/ Artificial Intelligence Feeds Need for Speed Technology is being used to fast-track radiation therapy plans and conserve clinical resources

Radiation therapy is simple in its concept: high- energy radiation can damage and destroy cells, so beams of radiation are directed at a tumour to kill cancer cells. However, the treatment must also carefully minimize the dose to nearby organs.

Actually creating a plan that balances these conflicting requirements can be incredibly complex—it requires dedicated time from a team of highly trained experts. Each patient’s anatomy and tumour shape are unique, and it takes a lot of clinical resources and expertise to create a high- quality plan.

That may not be the case for much longer. Dr. Thomas Purdie and his team, including Dr. Chris McIntosh, have used the power of artificial intelligence (AI) to develop a new system that can “The technology allows radiation medicine teams to

create a high-quality plan in minutes— take on more complex cases and provide precision

faster than current approaches, which can take medicine to more patients,” says Dr. Purdie. days. The technology, known as AutoPlanning, uses machine learning to harvest information from a Earlier this year, UHN announced that massive database of proven radiation therapy plans AutoPlanning has been licensed to RaySearch from Princess Margaret Cancer Centre. Laboratories of Sweden with the help of UHN’s Technology Development and Commercialization While no two patients are identical, there can be Office. The deep learning algorithms of the similarities. The AutoPlanning AI can evaluate AutoPlanning system will be integrated into many features in a patient’s images, and find other RaySearch’s RayStation treatment planning system patients in the database with similar features. Then, next year. Johan Löf, CEO of RaySearch, says, it builds a radiation therapy plan for the new patient “This technology has the potential to make a huge based on information in the plans of patients with contribution to patient care. I am delighted to be similar features. able to bring its benefits to centers around the world as part of the RayStation platform.” With thousands of high-quality plans to learn from, the system rapidly adapts and optimizes the plan to Images: (above) Dr. Thomas Purdie; (opposite page) radiation suit the new patient. therapy requires precise targeting and planning to account for a patient’s unique anatomy and tumour shape.

12

From Building Blocks to BlueRock BlueRock Therapeutics receives historic investment to advance stem cell research

Toronto’s stem cell and regenerative medicine development facilities in Toronto, New York and ecosystem gained a major player with the Boston. The Toronto facility will employ up to 70 establishment of a new biotechnology company, scientists and technical staff when fully functional. BlueRock Therapeutics, in December 2016. The company, co-founded by world-renowned UHN Sparked by the discovery of stem cells at UHN researchers, Drs. Gordon Keller and Michael more than 50 years ago, the local stem cell Laflamme, will advance novel stem cell-based research community is home to leading centres treatments for a variety of diseases, such as such as UHN’s McEwen Centre for Regenerative cardiovascular disease and Parkinson disease, in a Medicine and the Centre for Commercialization state-of-the-art 10,000 square foot facility. of Regenerative Medicine. BlueRock now joins this vibrant cluster of excellence in regenerative One of the first innovations that will be developed medicine, reinforcing Toronto’s world-class by the company is an approach to regenerate and reputation in the field. repair damaged heart muscles, co-created by the two UHN researchers. Drs. Keller and Laflamme BlueRock builds upon developed a way to coax stem cells into becoming specialized heart muscle cells called cardiomyocytes. Toronto’s excellence in These cells, when introduced into the heart, act like building blocks—incorporating into the heart tissue stem cell research. and making the heart stronger by repairing muscle damage caused by heart attacks or abnormal heart “The concentration of stem cell research resources rhythms. and expertise that we have is unparalleled,” says Dr. Keller, who is also the Director of the McEwen “We’ve had a lot of research breakthroughs in the Centre. “Establishing BlueRock Therapeutics is a past several years and with BlueRock we can now visionary move that will lead to new therapies for move them from the laboratory to the clinic to help currently untreatable diseases.” patients,” said Dr. Laflamme during the launch event, which was attended by federal and provincial UHN’s Technology Development and ministers and the Premier of Ontario. Commercialization Office worked closely with all partners to negotiate and execute the license BlueRock was made possible by Bayer AG and agreements for the foundational intellectual Versant Ventures, who provided US$225 million in property, as well a master research agreement to seed funding. The funds, which represent one of the fund future work. largest biotechnology investments in history, will be used to build and support research and Image: (L-R) Dr. Gordon Keller and Dr. Michael Laflamme.

14

Therapies are being developed by BlueRock that involve coaxing stem cells into becoming specialized heart muscle cells, which are reintroduced into damaged hearts to restore function.

Support>Discovery>Impact Support

New funding spurs world-class innovation

Federal Support for Basic Research Funding Proactive Research UHN was the top-funded research hospital in A team of researchers led by Dr. Rosemary the Canadian Institutes of Health Research’s Martino received US$8.5 million from the Patient- 2016–2017 Foundation and Project Grant Program Centered Outcomes Research Institute. The competitions. funding will support a multi-site study, called PRO-ACTIVE, that will focus on evaluating the For the Foundation Grant Program competition, effectiveness of proactively providing therapy UHN recieved a total of $22.9 million in funding to help those with head and neck cancer who for eight awards—representing the second highest experience difficulty swallowing. These patients number of awards given to a single institution and a often experience serious difficulties swallowing success rate almost double the national average. as a result of the location of the tumour or the radiotherapy used to treat it. These projects were led by Dr. Cheryl Arrowsmith (gene packaging in cancer), Dr. Robert Chen (brain Multidisciplinary expertise across UHN will connections in movement disorders), Dr. Myron support the study: Quantitative Imaging for Cybulsky (immune cells in blood vessel disease), Personalized Cancer Medicine will provide medical Dr. John Dick (leukemia stem cells), Dr. Mitsu imaging and radiation therapy solutions to enhance Ikura (the role of calcium in cancer growth), Dr. the reliability of study data; and Health Informatics Rama Khokha (genetic and environmental factors Research will customize technology solutions to driving cancer), Dr. Aaron Schimmer (therapeutic support the high-quality collection of patient- strategies for leukemia) and Dr. Gang Zheng reported outcomes and clinical research data. (nanotechnology for anti-cancer drug delivery). PRO-ACTIVE was selected through a highly Similarly, UHN fared well above the national competitive review process in which patients, average in the Project Grant Program competition, caregivers and other stakeholders joined scientists to with 22 projects receiving a total of $17.9 million. evaluate the proposals.

16 Building Capacity for Innovation Advancing Cancer Immune Therapy The Canada Foundation for Innovation awarded Two projects, led by UHN researchers Dr. Pamela $20.9 million to UHN for state-of-the-art research Ohashi and Dr. Mathieu Lupien, were selected for infrastructure. Through its Innovation Fund, two funding by the Terry Fox Research Institute. projects received large-scale awards. The first was the Princess Margaret Cancer Centre Precision Dr. Ohashi will receive $5.41 million to advance Medicine Program (led by Dr. Brad Wouters), her investigations into the use of cancer immune which was granted $11.8 million—the second therapy—a strategy that uses the body’s immune largest award in this competition—to develop new system to kill cancer cells. A world-renowned ways of profiling tumours. The second, CenteR pioneer in this field and the Co-Director of UHN’s for Advancing Neurotechnological Innovation to Tumour Immunotherapy Program, Dr. Ohashi will Application (CRANIA) (led by Dr. Milos Popovic), use the funds to develop and evaluate new immune was awarded $6.5 million to create new therapies therapies for high-grade serous ovarian cancer, the for neurological diseases and conditions. deadliest type of ovarian cancer.

Through the John R. Evans Leaders Fund, UHN Dr. Lupien will receive $2.25 million towards his secured $2.6 million for projects led by Dr. Bryan immune therapy research. His project will focus on Coburn (personalized microbiology); Dr. Adam advancing immune therapy for women with triple- Gehring (immune therapy for viral hepatitis); Dr. negative breast cancer, a type of cancer that tends to David Jaffray (robotic radiobiology); Dr. Michael have lower survival and higher recurrence rates. Laflamme (repair of injured hearts using stem cells); Dr. Tracy McGaha (tumour immunology); Dr. These projects were two of six funded projects, Philippe Monnier (retinal and neurodegenerative representing approximately 30% of total funds diseases); and by Dr. Mathieu Lupien (new awarded nationally. treatments for difficult-to-treat cancers).

17 Support>Discovery>Impact Discovery

A selection of top research findings

Clearing the Way The Magnificent 17 Stroke of Genius Nanoparticles are microscopic A research team led by Dr. Jean This year, a first-of-its-kind particles that can be linked to Wang has developed a genetic app was launched to provide anti-cancer drugs for delivery test that better predicts which clinicians with best practice to tumours. While effective leukemia patients will respond rehabilitation strategies for in experimental systems, to standard therapies. The test’s patients with arm impairments nanoparticles often fail in prediction is based on 17 genes due to stroke. patients because they become found in leukemia stem cells, trapped in the liver and do not which are instrumental in disease The ViaTherapy app, developed reach the tumour. initiation and recurrence. through a global collaboration led by rehabilitation researchers To identify the reason for this, a The test was created to help Drs. Mark Bayley and Steven team led by Dr. Ian McGilvray those with a type of leukemia Wolf (Emory University), is the and the University of Toronto’s known as acute myeloid result of more than five years Dr. Warren Chan examined leukemia, which is notoriously of research by a panel with how nanoparticles interact with difficult to treat: standard expertise in physiatry, neurology liver cells. They found that therapies fail in up to 60% of and physical and occupational nanoparticles slow down upon young adults and 85% of older therapy. entry into the liver from the adults with the disease. blood stream—giving liver cells The app assists physicians in time to eliminate them from the By identifying which patients recalling established stroke body. will not respond to standard therapies and in learning about therapies, the test could help new ones, making it easier for These results suggest that future avoid unnecessary treatments, them to evolve their treatment strategies should consider ways and identify those who may plans based on how far along the to condition the liver to reduce benefit from more experimental patient is in their recovery. nanoparticle removal. Tsoi KM, et or intensive treatment strategies. www.viatherapy.org. al. Nat Mater. 2016 Nov;15(11):1212-1221. Plans are underway to evaluate the test in a clinical trial. Ng SW, et al. Nature. 2016 Dec 15;540(7633):433-437. 18 A Gut Reaction Assisted Dying at UHN Protecting Brains A study led by Dr. Robert A report describing UHN’s More than 216 million people Inman showed that immune implementation of an assisted worldwide suffer from malaria, cells originating in the gut may dying program, led by Dr. a disease caused by parasite- promote disease in a form of Madeline Li, was published in infected mosquitos. If left arthritis known as ankylosing the New England Journal of untreated, it can progress to spondylitis (AS). Medicine. cerebral malaria, which can cause irreversible brain damage and This type of arthritis is Since February 2016, medical death. characterized by painful swelling providers in Canada have been in the back and neck joints that delivering medical assistance Based on the observation that occurs when the immune system in dying (MAiD) to eligible people with cerebral malaria attacks the body’s cells. patients. However, there is little have low levels of the protein information on the best way to Ang-1, Dr. Kevin Kain used Dr. Inman discovered a type of implement MAiD in a hospital. experimental models to gain immune cell that develops in UHN’s report is intended to a better understanding of the the gut—known as a mucosal- help address this knowledge gap. role of Ang-1 in the disease. associated invariant T cell—and He found that Ang-1 protects that promotes harmful joint Briefly, UHN’s program consists blood vessels in the brain inflammation. of voluntary medical teams during cerebral malaria, and that who assess eligibility, ensure treatment with Ang-1 improved These findings strengthen the informed consent and deliver survival compared to treatment possibility that immune cells the intervention. It also includes with conventional therapy. originating in the gut play a a committee that provides These exciting findings suggest role in AS, while providing new oversight, reports metrics and that Ang-1–based therapies molecular targets that could stewards data. During its first can be developed and tested inform the development of new year of operation, the program to improve outcomes for this treatments. Gracey E, et al. Ann provided MAiD to 19 patients. globally relevant disease. Higgins Rheum Dis. 2016 Dec;75(12):2124-2132. Li M, et al. N Engl J Med. 2017 May SJ, et al. Sci Transl Med. 2016 Sep 25;376(21):2082-2088. 28;8(358):358ra128. 19 Support>Discovery>Impact Impact

How research at UHN is improving health care

Safety Device Inspired by Nature A Superior Test for Sleep Apnea NeuroShield has been referred to as an ‘airbag An at-home sleep apnea test known as BresoDx is for the brain’. It was launched by Bauer, a leading now available to Ontario patients for the first time hockey equipment manufacturer, at a press as the result of a unique MaRS program. conference attended by the company’s spokesman and hockey legend Mark Messier. The breakthrough device—invented by Drs. Hisham Alshaer, T Douglas Bradley and Geoff The collar-like device sits around an athlete’s neck Fernie—is available at sleep clinics across the and applies a slight pressure, increasing the volume province. Ontario patients can use BresoDx to test of venous blood in the brain. The excess blood for sleep apnea in the comfort of their homes rather creates a ‘cushion’ between the skull and the delicate than in a sleep laboratory. It is the first technology tissues of the brain, protecting the latter against the to complete the MaRS EXCITE program, an microscopic damage caused by blows to the head. innovative initiative that accelerates the adoption of The concept for the device was inspired by the health technology in Ontario. woodpecker’s physiology, which protects the bird’s brain while drumming its beak against trees. Sleep apnea affects around 10% of adults, yet fewer than 15% of North Americans who have the Dr. Joseph Fisher was one of the three clinicians condition have been diagnosed. Left untreated, sleep who developed NeuroShield. The device was apnea leads to chronic sleeplessness and an increased evaluated for safety in clinical trials involving high risk of developing more serious conditions such as school soccer and football players, although device’s stroke and heart failure. ability to protect against concussions has not yet been validated. Q30 Innovations, a US-based By enabling the launch of BresoDx across the research and development company, acquired the province, the Ministry of Health and Long-Term commercial rights for the device and partnered with Care is paving the way for early diagnosis and Bauer to bring it to market. treatment of sleep apnea.

20 Inventor of the Year DR. CHRISTOPHER PAIGE

Sights Set on Helping the World Dr. Christopher Paige received MolecuLight i:X is a handheld device that uses fluorescence imaging to visualize bacteria in the 2016 award for his work in wounds. The device provides doctors with a quick readout of the status of wounds and infections— immune-oncology. He developed providing important health insights that are otherwise invisible to the naked eye. a therapeutic approach whereby a

The technology was developed at UHN by Dr. patient’s cancer cells are removed, Ralph DaCosta and spurred the creation of the MolecuLight spin-off company. Now, it is poised engineered to produce certain for world-wide adoption: a distribution agreement has been signed between MolecuLight and UK- chemical messengers and re- based Smith & Nephew that will put the technology into the hands of clinicians and patients around the introduced to the patient, which world. then stimulates immune cells to “MolecuLight i:X enhances clinicians’ ability to choose the right therapy, at the right time for their have potent anti-cancer activity. A patient,” says Dr. Andy Weymann, Chief Medical Officer at Smith & Nephew. The device’s ability clinical trial is now underway and to visualize wounds and infections will help guide wound management and treatment, contribute to the technology was licensed by the the monitoring of hospital-acquired infections, and aid hospital-based programs that aim to minimize UHN company AvroBio Inc. unnecessary use of antibiotics. UHN Foundations Making a difference by helping research grow

The Princess Margaret Cancer Foundation Toronto General & Western Hospital Foundation Toronto Rehab Foundation

22 Putting Patients First The Princess Margaret Cancer Foundation

The transformation, which started in May 2017, includes renovation of the Blood Collection Centre (artist’s rendering, left) and a fully redesigned and renovated Murray Street entrance (artist’s rendering, right)—both of which will improve the patient experience.

This year, The Princess Margaret (PM) Cancer The redesigned facility will enable blood samples Foundation launched its Transformation Campaign. to be analyzed in a more rapid and efficient manner, With a goal of raising $50 million in donations, delivering robust information to scientists for the campaign supports a multi-phase project to discovering new ways to individualize cancer care. transform the facilities at PM Cancer Centre— One such approach is the examination of circulating improving the patient experience from the moment tumour DNA, which comprises genetic material they step through the doors. that is released into the blood by certain tumours. By decoding the sequence of this genetic material, Approximately one in six patients volunteers to scientists can develop tests to monitor a patient’s participate in a clinical trial during their cancer response to therapy or to predict the effectiveness journey. These patients collectively donate more of novel anti-cancer drugs. than 26,000 blood samples each year toward finding new and improved ways of treating cancer. The “This project will facilitate clinical research, helping efficient collection, management and storage of to ensure that our world-class team can meet the these precious samples are critical to bench-to- individual needs of every patient,” explains Dr. bedside research. Mary Gospodarowicz, Medical Director of the PM Cancer Centre. To this end, part of the Transformation Project will include a redesign of the Blood Collection Centre. By providing a seamless integration of research It will undergo an expansion and reorganization throughout the cancer journey, this highly to accommodate three more accessible collection functional transformation will advance the stations, an expanded reception and waiting area institution’s committment to patient-centered care. and key functional upgrades. It will also accelerate research and innovation of new treatments and technologies that put patients’ needs first. A Night of Discovery Toronto General & Western Hospital Foundation

(Left image) The Discovery Ball featured live music; (top right image, L-R) an on stage discussion between Krembil Director Dr. Don Weaver and science communicator Jay Ingram; (bottom right image) buttons for scientific attendees.

The first Discovery Ball—a fundraising initiative The event included a raffle for prizes such as a led by Toronto General & Western Hospital diamond rivière necklet and a live auction, hosted Foundation—took place on October 15, 2016. The by broadcaster, award-winning writer and producer goal of the event was to promote the Krembil Husein Madhavji capped the event. The highest Research Institute’s research successes and raise bidders won the opportunity to tour the labs of money to support research into cures for diseases of Dr. Weaver and Krembil Senior Scientist Dr. Mohit the brain, spine, bones, joints and eyes. Kapoor, a prize that further underscored the discovery theme. A candid conversation between Krembil Director Dr. Donald Weaver and science communicator Jay The event pairs people Ingram was featured on the main stage. Researchers in attendance wore “ask me about my research” committed to advancing buttons, encouraging discussions on the valuable work happening at the Krembil and giving the health care with Kremil philanthropists an opportunity to understand how important their contributions were to developing researchers. cures, while creating an air of collaboration and discovery. The event raised nearly $1 million to support research at the Krembil. Because of its success, The Discovery Ball was the brainchild of Stacey the Discovery Ball will continue as a staple of the Krembil, who was also co-chair of the planning Toronto General & Western Hospital Foundation’s committee with Dr. Michael Baker, who hosted fundraising efforts, with the next event scheduled the event. The night was well attended, with nearly for October 2018. 400 distinguished guests, including philanthropists, UHN leadership and Krembil-affiliated researchers.

24 Where Incredible Happens Toronto Rehab Foundation

(Left and middle images) Dr. Milos Popovic (red tie) and his trainees demonstrating the capabilities of REL’s specialized equipment; (right image, L-R) Maris Uffelmann and Dean Connor, donors who pledged $1 million in support of REL.

At Toronto Rebilitation Institute (TRI), researchers “There are few moments in life when you have the work tirelessly to develop new therapies and power to significantly improve the lives of people products that restore function after illness or around you,” says Dean. “We are happy to be able injury and enable independent living within the to help.” community. REL is led by Dr. Milos Popovic, the TRI Chair in In October 2015, the Toronto Rehab Foundation Spinal Cord Injury Research, and employs more launched its Where Incredible Happens campaign, than 40 researchers, trainees and staff. Dr. Popovic’s which aims to raise $100 million to support TRI research has yielded novel technologies—such as researchers, programs and facilities, which are functional electrical stimulation therapy—that instrumental in developing life-changing inventions. produce unparalleled levels of recovery in people Inspired by TRI’s work, Dean Connor, the affected by stroke or spinal cord injuries: they President and CEO of Sun Life Financial and a have improved patients’ balance and restored Vice-Chair of UHN’s Board of Trustees, agreed to their ability to walk, reach and grasp objects. His lead the campaign. research is also making important advances in brain-machine interfaces, functional assessment Dean and his wife, Maris Uffelmann, demonstrated tools, rehabilitation techniques and neuroprosthesis their personal commitment to the campaign systems. through an incredible $1 million gift to support TRI’s Rehabilitation Engineering Lab (REL). REL Dean and Maris’s generous gift is enabling REL to is located at Toronto Rehab’s Lyndhurst Centre, undertake two high-risk, high-payoff projects. The home of Canada’s largest rehabilitation program funds are supporting trainees and staff examining devoted to spinal cord injuries. the use of electrical stimulation to treat depression and of brain-machine interfaces to restore upper- limb function in stroke survivors. Research Distinctions Selected honours bestowed upon UHN researchers

Dr. Elizabeth Badley Dr. John Dick 2017 Distinguished Scholar Award, Association of 2017 Tobias Award Lecture, International Society Rheumatology Health Professionals for Stem Cell Research 2016 Gold Leaf Prize for Discovery, Canadian Dr. Philippe Bedard Institutes of Health Research 2017 William E. Rawls Prize, Canadian Cancer Tier 1 Canada Research Chair in Stem Cell Biology Society (renewal) 2017 Keio Medical Science Prize, Keio University Dr. David Cescon 2017 Dr. Elizabeth Eisenhauer Early Drug Dr. Michael Fehlings Development Young Investigator Award, 2017 David Lostchuck Memorial Research Award, Canadian Cancer Trials Group Canadian Spinal Research Organization

Dr. Vinod Chandran Dr. Eleanor Fish 2017 Young Investigator Award, Canadian 2017 Leadership in Advocacy Award, Research Rheumatology Association Canada

Dr. B Catharine Craven Dr. Mary Gospodarowicz 2017 Award of Merit, Canadian Association of 2017 Wendy Lack Women of Action Scientific Physical Medicine & Rehabilitation Award, Israel Cancer Research Fund

Dr. Marcelo Cypel Dr. Housheng Hansen He Tier 2 Canada Research Chair in Lung 2017 New Investigator Award, The Terry Fox Transplantation (renewal) Research Institute

Dr. Karen Davis Dr. Mitsuhiko Ikura 2017 Outstanding Pain Mentorship Award, Tier 1 Canada Research Chair in Cancer Structural Canadian Pain Society Biology (renewal)

Dr. Daniel De Carvalho Dr. Jonathan Irish Tier 2 Canada Research Chair in Cancer Epigenetics President, American Head & Neck Society and Epigenetic Therapy Dr. Michael Jewett Drs. Daniel De Carvalho and Mathieu Lupien 2017 Exceptional Leadership in Patient Involvement 2017 Bernard and Francine Dorval Prize, Canadian in Cancer Research Award, Canadian Cancer Cancer Society Research Alliance

Dr. Eleftherios Diamandis Dr. Anthony Lang 2017 Lifetime Achievement Award, Ontario Society 2017 MDS Pan-American Section Leadership of Clinical Chemists Award, International Parkinson and Movement Disorder Society

26 Dr. Gary Levy Dr. Frances Shepherd 2017 Lifetime Achievement Award, Canadian 2017 Addario Lectureship Award, Bonnie J. Society of Transplantation Addario Lung Cancer Foundation 2017 Women for Oncology Award, European Dr. Andres Lozano Society for Medical Oncology 2017 Khwarizmi International Award, Iranian Research Organization for Science and Dr. Lillian Siu Technology Member, Board of Directors, American Association 2017 Bachmann-Strauss Prize for Excellence in for Cancer Research Dystonia Research, Michael J. Fox Foundation for Parkinson’s Research Dr. Charles Tator Officer, Order of Canada (promotion from Dr. Mary Pat McAndrews Member) 2017 Excellence in Research Award, Canadian League Against Epilepsy Dr. Ming-Sound Tsao 2016 Dr. Joseph Pater Excellence in Clinical Trials Dr. Brian O’Sullivan Research Award, Canadian Cancer Trials Group 2017 O. Harold Warwick Prize, Canadian Cancer Society Dr. Michael Tymianski Member, Order of Canada Dr. Amit Oza GOC Presidential Medal, Society of Gynecologic Dr. Murray Urowitz Oncology of Canada 2017 Distinguished Clinical Investigator Award, American College of Rheumatology Dr. Christopher Paige 2017 Leadership in Advocacy Award, Research Dr. Sharon Walmsley Canada Member, Order of Canada

Dr. Kara Patterson Dr. Minna Woo 2017 Innovation and Advancement Award, Ontario Tier 2 Canada Research Chair in Signal Physiotherapy Association Transduction in Diabetes Pathogenesis (renewal)

Dr. Trevor Pugh Dr. Bradly Wouters 2017 New Investigator Award, The Terry Fox Tier 1 Canada Research Chair in Hypoxia and the Research Institute Tumour Microenvironment

Dr. Milica Radisic Dr. Azadeh Yadollahi 2017 Steacie Prize for Natural Sciences, E.W.R. Early Researcher Award, Ontario Ministry of Steacie Memorial Fund Research, Innovation and Science Tier 2 Canada Research Chair in Functional Cardiovascular Tissue Engineering (renewal) Dr. José Zariffa Early Researcher Award, Ontario Ministry of Dr. Gary Rodin Research, Innovation and Science 2017 Bernard Fox Memorial Award, International Psycho-Oncology Society

27 UHN Research Institutes

Krembil Research Institute

Princess Margaret Cancer Centre

Toronto General Hospital Research Institute

Techna Institute

Toronto Rehabilitation Institute

28 Krembil Research Institute

TOTAL RESEARCHERS 216 RESEARCH SPACE 154,001 sq. ft.

Total Appointed Researchers 92 EXTERNAL FUNDING $52,659,561 Senior Scientists 31 Scientists 11 TOTAL TRAINEES 120 Affiliate Scientists 15 Fellows 48 Emeritus 2 Graduate Students 72 Clinician Investigators 33 TOTAL STAFF 276 Clinical Researchers 124 PUBLICATIONS 947

Research Council Director and Chair, Krembil Research Institute Donald Weaver Division Head, Fundamental Neurobiology Peter Carlen Division Head, Healthcare & Outcomes Research Aileen Davis Division Head, Brain Imaging & Behaviour – Systems Neuroscience Karen Davis Division Head, Genetics & Development James Eubanks Co-Director, Donald K. Johnson Eye Institute Valerie Wallace Clinical Representative, Arthritis Program Robert Inman Research Director, Arthritis Program Mohit Kapoor Medical Director, Arthritis Program Nizar Mahomed Chair, Trainee Affairs Committee Frances Skinner Executive Director, Research Operations Lisa Alcia Vice President and Site Lead, Toronto Western Hospital Janet Newton Executive Vice President, Science and Research Bradly Wouters Researchers Brain, Imaging & Mojgan Hodaie Scientists James Eubanks Behaviour-Systems Affiliate Scientists Jérémie Lefebvre Michael Fehlings Neuroscience Mark Guttman Ivan Radovanovic Robert Inman Senior Scientists Clement Hamani Taufik Valiante Mohit Kapoor Jonathan Brotchie Walter Kucharczyk Affiliate Scientists Lyanne Schlichter Robert Chen Magdy Hassouna Elise Stanley Karen Davis Fundamental Liang Zhang Joan Wither William Hutchison Neurobiology Georg Zoidl Scientists Sidney Kennedy Senior Scientists Nigil Haroon Andres Lozano Peter Carlen Genetics & Lorraine Kalia Mary Pat McAndrews Frances Skinner Development Suneil Kalia David Mikulis Shuzo Sugita Emeritus Armand Keating Antonio Strafella Michael Tymianski Charles Tator Affiliate Scientist Scientists Donald Weaver Senior Scientists Sowmya Viswanathan Jonathan Downar Cathy Barr

29 Krembil Research Institute

Healthcare & Efrem Mandelcorn Barry Greenberg Colin Shapiro Outcomes Research Daniel Mandell Raed Hawa Abdu Sharkawy Emeritus Shane McInerney Robert Iwanochko Sanjay Siddha Murray Urowitz Roger McIntyre Sindhu Johnson Frank Silver Senior Scientists Renato Munhoz Ron Keren Martin Simons Elizabeth Badley Laura Passalent Kyle Kirkham Jeffrey Singh Aileen Davis Fayez Quereshy Stephen Kraft Mandeep Singh Dafna Gladman Y Raja Rampersaud Timo Krings Elizabeth Slow Nizar Mahomed David Rootman Debbie Kwan Sumeet Sodhi Cheryl Rosen Jeffrey Kwong Neilesh Soneji Scientist † Anthony Perruccio Allan Slomovic Robert Lam Martin Steinbach David Tang-Wai Wai-Ching Lam Barbara Stubbs Affiliate Scientists M Carmela Tartaglia Johnny Lau Khalid Syed Vinod Chandran Zahi Touma Stephen Lewis Peter Tai Paul Fortin Christian Veillette Joel Lexchin Susan Tarlo Monique Gignac M Elizabeth Wilcox Charles Lynde Maria Tassone Rosemary Martino Mateusz Zurowski Angela Mailis-Gagnon Karel terBrugge Mark Mandelcorn Graham Trope Patient-based Clinical Researchers Pirjo Manninen Karen Tu Clinical Research Ronit Agid Katie Marchington Paul Tumber Senior Scientist Jamil Ahmad Samuel Markowitz Andrea Veljkovic Anthony Lang Peter Ashby Patricia Marr Alexander Velumian Yaron Avitzur Connie Marras Lakshmi Venkatraghavan Donald K. Johnson Brian Baker Theodore Marras Herbert von Schroeder Eye Institute Paul Binhammer Eric Massicotte Adam Weizman Senior Scientists Jeff Bloom Steven McCabe Richard Wennberg Philippe Monnier Arthur Bookman Azadeh Moaveni Robert Willinsky Christopher Hudson Sarah Brode Rakesh Mohankumar David K Wong Valerie Wallace Richard Brull Ali Naraghi David T Wong Agnes Wong Esther Bui Ahtsham Niazi Jean Wong Scientist Yvonne Buys Ivy Oandasan Eric Yu Jeremy Sivak Simon Carette Darrell Ogilvie-Harris Affiliate Scientists Leanne Casaubon Allan Okrainec Moshe Eizenman J David Cassidy Christian Pagnoux John Flanagan Rodrigo Cavalcanti Daniel Panisko Brenda Gallie Jas Chahal Christine Papoushek Esther González Clara Chan Sagar Parikh Vincent Chan Philip Peng Clinician Kenneth Chapman Vitor Pereira Anahi Perlas Investigators Caroline Chessex Angela Cheung Aleksandra Pikula Dimitri Anastakis Atul Prabhu Danielle Andrade Ki Jinn Chin Maria Cino Sidney Radomski Heather Baltzer Sapna Rawal Mark Bernstein Michael Cusimano J Roderick Davey Shail Rawal Anuj Bhatia Aylin Reid Michael Brent J Martin del Campo Sherif El-Defrawy Rowena Ridout Daniel Buchman Jennifer Robblee Frances Chung W Mark Erwin Richard Farb Sandra Robinson Melanie Cohn Arjun Sahgal Robert Devenyi Paul Fraser David Frost David Salonen Dean Elterman Jorge Sanchez-Guerrero Alfonso Fasano Alberto Goffi Eyal Golan Paul Sandor Susan Fox Monica Scalco Kenneth Fung Ewan Goligher Allan Gordon Michael Schwartz Rajiv Gandhi Hemant Shah Timothy Jackson Brent Graham

30 Princess Margaret Cancer Centre

TOTAL RESEARCHERS 333 RESEARCH SPACE 416,488 sq. ft.

Appointed Researchers 82 EXTERNAL FUNDING $142,847,824 Senior Scientists 44 Scientists 16 TOTAL TRAINEES 259 Affiliate Scientists 18 Fellows 124 Assistant Scientist 1 Graduate Students 135 Emeritus 3 TOTAL STAFF 857 Cancer Clinical Research Unit (CCRU) Members 251 PUBLICATIONS 1,192

Research Council on Oncology (RCO) Director, PM Cancer Centre; Chair, RCO; Chair, Executive Committee (Interim) Rama Khokha Executive Committee Mitsuhiko Ikura, Rama Khokha, Mathieu Lupien, Pamela Ohashi, Gary Rodin, Aaron Schimmer, Vuk Stambolic, Ming-Sound Tsao, Brian Wilson, Gang Zheng Chair, Appointments Committee Rama Khokha Medical Director, Cancer Program Mary Gospodarowicz Medical Director, Laboratory Medicine Program Runjan Chetty Head, CCRU Amit Oza Head, Medical Oncology and Hematology Amit Oza Head, Radiation Medicine Fei-Fei Liu Chief, Surgical Oncology Gelareh Zadeh Executive Director, Research Operations Lisa Alcia Senior Vice President and Site Lead, PM Cancer Centre Marnie Escaf Executive Vice President, Science and Research Bradly Wouters Researchers Emeritus Razqallah Hakem Mathieu Lupien Norman Boyd David Hedley Tak Mak Richard Hill Naoto Hirano Tracy McGaha A Michael Rauth Doris Howell Mark Minden Mitsuhiko Ikura Benjamin Neel Senior Scientists Norman Iscove Pamela Ohashi Kenneth Aldape David Jaffray Emil Pai Cheryl Arrowsmith Jennifer Jones Christopher Paige Sylvia Asa Igor Jurisica Linda Penn David Brooks Gordon Keller Gilbert Privé Avijit Chakrabartty Rama Khokha Brian Raught Daniel De Carvalho Thomas Kislinger Gary Rodin Gerald Devins Lothar Lilge Robert Rottapel John Dick Fei-Fei Liu Aaron Schimmer Shereen Ezzat Geoffrey Liu Vuk Stambolic

31 Princess Margaret Cancer Centre

Ming-Sound Tsao Michael Baker Christine Cserti-Gazdewich I Alex Vitkin Dwayne Barber Bernard Cummings Brian Wilson David Barth Gilda da Cunha Santos Bradly Wouters Andrew Bayley Norma D’Agostino Gang Zheng Nathan Becker Laura Dawson Camilla Zimmermann Philippe Bedard Jan Delabie J Robert Beecroft Uday Deotare Scientists Akbar Beiki-Ardakani Neesha Dhani Laurie Ailles Jennifer Bell Robert Dinniwell Scott Bratman Robert Bell Susan Done Steven Chan Alejandro Berlin James Downar Ralph DaCosta Hal Berman Daniel Drucker Kim Edelstein Marcus Bernardini Alexandra Easson Benjamin Haibe-Kains Lori Bernstein Elena Elimova Housheng Hansen He Andrea Bezjak Christine Elser Michael Hoffman Ivan Blasutig Jaime Escallon Marianne Koritzinsky Scott Boerner Andrew Evans Mohammad Mazhab-Jafari Penelope Bradbury Hannaneh Faghfoury Faiyaz Notta Anthony Brade Ronald Feld Catherine O’Brien William Brien Peter Ferguson Trevor Pugh James Brierley Sarah Ferguson Rodger Tiedemann Robert Bristow Carina Feuz Gelareh Zadeh Dale Brown Antonio Finelli Karina Bukhanov Neil Fleshner Assistant Scientist Ronald Burkes Warren Foltz Christopher Marshall Marcus Butler Jeremy Freeman Jeannie Callum Anthony Fyles Affiliate Scientists Marco Carlone Lucia Gagliese Mark Bray Angela Cashell Steven Gallinger Eric Chen Charles Catton William Geddie Phedias Diamandis David Cescon Fred Gentili Ryan Dowling William Chapman Sandeep Ghai Mary Jane Esplen Tanya Chawla Sangeet Ghai Anthony Joshua Christine Chen Danny Ghazarian C Anne Koch Terry Cheng Ralph Gilbert Paul Kongkham Douglas Chepeha Caitlin Gillan Robert Kridel Runjan Chetty Meredith Giuliani Benjamin Lok Carol Cheung Rebecca Gladdy Michael Moran Charles Cho David Goldstein Michael Reedijk John Cho Pamela Goodwin Leonardo Salmena Young-Bin Cho Chiara Gorrini Liran Shlush James Chow Mary Gospodarowicz Suzanne Trudel Caroline Chung Rashmi Goswami Jean Wang Peter Chung Anand Govindarajan Paul Waterhouse Tae Bong Chung Paul Greig Wei Xu Tulin Cil Patrick Gullane Blaise Clarke Abha Gupta Cancer Clinical Research Sean Cleary Vikas Gupta Unit (CCRU) Tatiana Conrad Sara Hafezi-Bakhtiari Ayman Al Habeeb Tim Craig Masoom Haider Dominick Amato Andrew Crean Sarah Hales Eitan Amir Jennifer Croke Robert Hamilton Mostafa Atri Michael Crump Kathy Han

32 Anthony Hanbidge Andrew Matthew Lillian Siu Breffni Hannon Catherine Maurice Joyce So Aaron Hansen Taymaa May Anna Spreafico Robert Heaton Dawn Maze Boraiah Sreeharsha Joelle Helou David McCready Srikala Sridhar Aaron Hendler Allison McGeer Alexander Sun David Hodgson Andrea McNiven Carol Swallow Stefan Hofer Maurene McQuestion Joan Sweet David Hogg Hans Messner Tony Tadic Shao Hui Huang Ozgur Mete Ian Tannock Hyun-Jung Jang Fotios Michelis Anne Tierens Raymond Jang Barbara-Ann Millar Ants Toi Jeffrey Jaskolka Naomi Miller Emina Torlakovic Kartik Jhaveri Michael Milosevic John Trachtenberg Sarah Johnson Nadeem Moghal Richard Tsang John Kachura Eric Monteiro Hubert Tsui Suzanne Kamel-Reid Chantal Morel Theodorus van der Kwast Zahra Kassam Lyndon Morley Michael Velec Ebru Kaya Douglas Moseley Auro Viswabandya Harald Keller Carol-anne Moulton John Waldron Erin Kennedy Anna Marie Mulligan Richard Ward Korosh Khalili Rumina Musani Padraig Warde Tim-Rasmus Kiehl Alice Newman David Warr Dennis Kim Rinat Nissim Ilan Weinreb John Kim Martin O’Malley Kirsten Wentlandt Raymond Kim Anne O’Neill Lawrence White Tae Kyoung Kim Brian O’Sullivan Ian Witterick Jennifer Knox Amit Oza Rebecca Wong Hyang Mi Ko Demetris Patsios Jay Wunder Hatem Krema Bayardo Perez-Ordonez Karen Yee Monika Krzyzanowska Andrew Pierre Erik Yeo Vishal Kukreti Katherine Pisters Ivan Yeung Vathany Kulasingam Anna Porwit Eugene Yu Girish Kulkarni Anca Prica Toni Zhong Supriya Kulkarni Graeme Quest Alexandre Zlotta Kevin Kuo Albiruni Razak John Kuruvilla Donna Reece Stéphane Laframboise Julia Ridley David Lam Jolie Ringash Normand Laperriere Paul Ritvo Natasha Leighl Tara Rosewall Wey-Liang Leong Lorne Rotstein Wilfred Levin Marjan Rouzbahman Stéphanie Lheureux Anabel Scaranelo Madeline Li Heidi Schmidt Winnie Li Andre Schuh Patricia Lindsay Jack Seki Jeffrey Lipton Stefano Serra Christopher Lo Patricia Shaw Helen Mackay Nadine Shehata Ernie Mak Frances Shepherd Lisa Martin David Shultz Warren Mason Hassan Sibai

33 Toronto General Hospital Research Institute

TOTAL RESEARCHERS 397 RESEARCH SPACE 171,800 sq. ft.

Appointed Researchers 149 EXTERNAL FUNDING $72,491,550 Senior Scientists 63 Scientists 35 TOTAL TRAINEES 281 Affiliate Scientists 47 Fellows 104 Assistant Scientist 4 Graduate Students 177

Clinical Researchers 248 TOTAL STAFF 459

PUBLICATIONS 1,454

Research Council Director, TGHRI; Chair, TGHRI Research Council; Research Division Head (Acting), Experimental Therapeutics Mansoor Husain Research Division Head, Advanced Diagnostics Myron Cybulsky Research Division Head, Support, Systems & Outcomes Murray Krahn Clinical Program Head, Transplantation Atul Humar Clinical Program Head, Peter Munk Cardiac Centre Barry Rubin Physician-in-Chief; Clinical Program Head, Medical & Community Care Edward Cole Surgeon-in-Chief; Clinical Program Head, Surgical & Critical Care Shaf Keshavjee Chair, TGHRI Appointments Committee Thomas Waddell Group Lead, Communities of Health Shabbir Alibhai Group Lead, Cardiovascular Slava Epelman Group Lead, Infection & Immunity Adam Gehring Group Lead, Respiratory & Critical Care Mingyao Liu Group Lead, Metabolism Minna Woo Executive Director, Research Operations Lisa Alcia Senior Vice President and Site Lead, Toronto General Hospital Scott McIntaggart Executive Vice President, Science and Research Bradly Wouters Researchers Advanced Eleanor Fish Kumaraswamy Eldad Zacksenhaus Diagnostics Jason Fish Nanthakumar Li Zhang Senior Scientists Joseph Fisher York Pei Scientists Johane Allard John Floras Bruce Perkins Moumita Barua Peter Backx Tony Lam Barry Rubin Filio (Phyllis) Billia Daniel Cattran Gary Lewis James Scholey David Cherney Myron Cybulsky Mingyao Liu Katherine Siminovitch Bryan Coburn I George Fantus Michael Wheeler Shannon Dunn

34 Slava Epelman Jordan Feld Gary Rodin Vera Bril Anthony Gramolini Adam Gehring Peter Singer James Brunton Tianru Jin Michael Gollob Donna Stewart Jagdish Butany Ana Konvalinka J Andrea McCart David Urbach John Byrne Heather Reich Ian McGilvray Scientists Christopher Caldarone Clinton Robbins M Cristina Nostro Ana Carolina Alba Douglas Cameron Jonathan Rocheleau Nazia Selzner Anna Gagliardi Carl Cardella Paaladinesh Lena Serghides Bettina Hansen Jose Carvalho Thavendiranathan Kazuhiro Yasufuku Sarbjit Vanita Jassal Charles Chan Daniel Winer Affiliate Scientists Janet Raboud Christopher Chan Minna Woo Marisa Battistella Valeria Rac Cecilia Chaparro Affiliate Scientists Mamatha Bhat Beate Sander Anil Chopra Donald Branch Gail Darling Affiliate Scientists Michael Christian Hong Chang Gregory Downey Thomas Forbes Hance Clarke Peter Liu Anand Ghanekar Suzanne Fredericks Paula Cleiman Philip Millar David Grant Alan Fung Edward Cole Anna Sawka Raymond Hui Sherry Grace Evan Collins William Stansfield Shahid Husain Brian Hodges Jack Colman Florence Wong David Hwang M Jane Irvine Patricia Colton Assistant Scientist Stephen Juvet Adrienne Kovacs Richard Cooper Sonya MacParland Joel Katz Jane MacIver Adrian Crawley Thomas Lindsay Gail McVey Kenneth Croitoru Experimental Tereza Martinu Nicholas Mitsakakis Sharon Cushing Therapeutics Cheri McGowan Kathryn Nichol Robert Cusimano Senior Scientists Raymond Reilly Karen Okrainec Kasia Czarnecka-Kujawa T Douglas Bradley Sheila Riazi Marion Olmsted Patrick Darragh Mark Cattral Heather Ross Jacob Pendergrast Kathleen Dattilo Marc de Perrot Michael Sefton Rima Styra Tirone David Niall Ferguson Markus Selzner George Tomlinson Lorenzo Del Sorbo Herbert Gaisano Morris Sherman Alice Wei Diego Delgado Margaret Herridge Darrell Tan D Blake Woodside Neal den Hollander Atul Humar Terrence Yau Assistant Scientist Allan Detsky Mansoor Husain Assistant Scientists Andy Wong Michael Detsky Harry Janssen Andrzej Chruscinski Eleftherios Diamandis Kevin Kain Sara Santana Nunes Clinical Researchers Gina Dimitropoulos Keyvan Karkouti Vasconcelos Susan Abbey George Djaiani Rupert Kaul Peter Adamson Michael Domanski David Kelvin Support, Systems & Oyedele Adeyi Eugene Downar Shaf Keshavjee Outcomes Ganesh Annamalai Michelle Downes Lakshmi Kotra Senior Scientists Carmen Avila-Casado Andrei Drabovich Michael Laflamme Shabbir Alibhai Mitesh Badiwala James Duffin Gary Levy Anne Bassett Mrinalini Balki Vladimir Dzavik Ren-Ke Li Claire Bombardier Meyer Balter David Ellis Nancy Olivieri Angela Cheung Joanne Bargman Paul Ellis Milica Radisic Peter Cram Carolina Barnett Eddy Fan Vivek Rao Abdallah Daar Alan Barolet Michael Farkouh Thomas Waddell Gunther Eysenbach W Scott Beattie Ludwik Fedorko Sharon Walmsley Alastair Flint Chaim Bell Denice Feig Richard Weisel Allan Kaplan Lee Benson Christopher Feindel Scientists Moira Kapral Matthew Binnie Olavo Fernandes Vijay Chauhan Murray Krahn Robert Bleakney Sandra Fischer Chung-Wai Chow Douglas Lee Andrea Boggild Jolene Fisher Marcelo Cypel Charmaine Lok Isaac Bogoch David Flamer Satya Dash Robert Nolan Ari Breiner Steven Friedman

35 Toronto General Research Hospital Institute

Scott Fung Kelly MacDonald Graham Roche-Nagle Marcin Wasowicz Michael Gardam Thomas MacMillan Patrik Rogalla Greg Wells Susan George Christine Maheu Coleman Rotstein Cynthia Whitehead Peter Giacobbe Susanna Mak John Rutka Duminda Wijeysundera Mihaela Ginj Jeffrey Man Irving Salit David Wiljer Shiphra Ginsburg Cedric Manlhiot Margaret Salmon Stephen Wolman Wayne Gold Katherine Marseu Gonzalo Sapisochin Rene Wong Roger Goldstein Azad Mashari Zion Sasson Anna Woo Avrum Gotlieb Tony Mazzulli Jeffrey Schiff Nicole Woods John Granton Stuart McCluskey Leonard Schwartz Linda Wright Gordon Greenberg Michael McDonald Joerg Schwock Robert Wu Sandra Grgas Micheal McInnis Phillip Segal Paul Yip Aliya Gulamhusein Robin McLeod Rita Selby Bernard Zinman Andrew Ha Rory McQuillan Mohammad Shafiee Flavio Habal Karen McRae Maureen Shandling Kate Hanneman Sangeeta Mehta Shane Shapera Paula Harvey Massimiliano Meineri Eran Shlomovitz Laura Hawryluck Ravi Menezes Manohar Shroff Carol Heck Adam Millar Naveed Siddiqui Edward Hickey Shikha Mittoo Mark Silverberg Michelle Hladunewich Ravi Mohan Candice Silversides Brian Hodges Andrew Morris Lianne Singer Eric Horlick Istvan Mucsi Sunita Singh Susy Hota Patricia Murphy Samir Sinha Douglas Ing Gary Newton Anna Skorzewska Nasir Jaffer Elsie Nguyen Peter Slinger Angela Jerath Geoffrey Nguyen Kenneth Sniderman Rohan John Marta Novak Miranda So Christine Jonas-Simpson Erwin Oechslin Sanjeev Sockalingam Tuula Kalliomäki Gerald O’Leary Christine Soong Sonja Kandel George Oreopoulos Danna Spears Hans Katzberg Mark Osten Coimbatore Srinivas Rita Katznelson Mirek Otremba A Hillary Steinhart Edward Keystone Maral Ouzounian Marshall Sussman Jay Keystone Christopher Overgaard Richard Swinson Yasmin Khan Mini Pakkal Adrienne Tan S Joseph Kim Blake Papsin Kong Teng Tan John Kingdom Rulan Parekh John Thenganatt Caroline Kramer John Parker Seng Thipphavong Kulamakan Kulasegaram Matteo Parotto Jussi Tikkanen Deepali Kumar Jesse Pasternak Lianne Tile Ayelet Kuper Keyur Patel Kathryn Tinckam Bindee Kuriya Todd Penner Sheldon Tobe Karim Ladha David Pothier Kathryn Trottier Megan Landes Susan Poutanen Wendy Tsang Stephen Lapinsky Lisa Puchalski Ritchie Alice Tseng Patrick Lawler Harry Rakowski Jacob Udell Christie Lee Dina Reiss Amar Uxa Lani Lieberman Eberhard Renner Glen Van Arsdell Leslie Lilly Ravi Retnakaran Annette Vegas Yulia Lin Robert Richardson Allan Vescan Jessica Liu Michael Robinette Andrea Waddell Louis Liu Gail Robinson Rachel Wald Alexander Logan S Lucy Roche Paul Walfish

36 Techna Institute

TOTAL RESEARCHERS 47 TOTAL TRAINEES 21 Core Leads 9 Fellows 8 Scientists 3 Graduate Students 13 Affiliated Faculty 35 TOTAL STAFF 106 RESEARCH SPACE 27,820 sq. ft. Technology Development Team 45 Other Staff 61 EXTERNAL FUNDING $11,586,816 PUBLICATIONS 346

Techna Leadership Team Director, Techna Institute David Jaffray Director, Research Faculty, Physical Sciences Director, Clinical Processes Howard Abrams J Paul Santerre Senior Director, Techna Innovation Luke Director, Commercialization Mark Taylor Brzozowski Executive Vice President, Science and Research Director, Knowledge Transfer Nicole Harnett Bradly Wouters Director, Research Faculty, Clinical Jonathan Irish Researchers Design & Engineering for Jean-Pierre Bissonnette Peter Rossos Health Catherine Coolens Affiliated Faculty Core Lead John de Almeida Brenda Gallie Joseph Cafazzo Gabor Fichtinger Alejandro Jadad Affiliated Faculty Howard Ginsberg Michael Jewett Emily Seto Justin Grant Gordon Tait Patricia Trbovich Mojgan Hodaie Christian Veillette Andrew Hope Guided Therapeutics Mohammad Islam Nanotechnology & Core Leads Daniel Létourneau Radiochemistry Jonathan Irish Andres Lozano Core Leads David Jaffray Kieran Murphy Ur Metser Walter Kucharczyk Narinder Paul Gang Zheng Scientists Thomas Purdie Affiliated Faculty Margarete Akens Dheeraj Rajan John Valliant Arash Zarrine-Afsar Teodor Stanescu Affiliated Faculty Robert Weersink Photonics Dionne Aleman Bernd Wintersperger Core Lead Timothy Chan Kazuhiro Yasufuku Brian Wilson James Drake Scientist Claire McCann Informatics & Ralph DaCosta Cynthia Ménard Communications Technology Affiliated Faculty Alexandra Rink Core Leads I Alex Vitkin Michael Sherar Igor Jurisica

37 Toronto Rehabilitation Institute

TOTAL RESEARCHERS 118 RESEARCH SPACE 55,965 sq. ft.

Appointed Researchers 111 EXTERNAL FUNDING $16,402,393 Senior Scientists 23 Scientists 21 TOTAL TRAINEES 102 Affiliate Scientists 67 Fellows 25 Graduate Students 77 Clinical Researchers 7 TOTAL STAFF 104

PUBLICATIONS 508

Research Advisory Council (RAC) Director, TRI; Chair, RAC Geoff Fernie Associate Academic Director of Research, TRI Susan Jaglal Associate Scientific Director of Research, TRI Milos Popovic Team Leaders Mark Bayley, Angela Colantonio, Tilak Dutta, Robin Green, Owen Lyons, Katherine McGilton, Alex Mihailidis, Paul Oh, B Catharine Craven, Catriona Steele, Yana Yunusova Sub-Committee Chairs B Catharine Craven, Susan Jaglal, Katherine McGilton, Milos Popovic Business Development & Organization Effectiveness Catharine Hancharek, Anthony Palma Research Services & Operations Lois Ward Senior Vice President and Site Lead, Toronto Rehab Susan Jewell Executive Vice President, Science and Research Bradly Wouters Researchers Acquired Brain Injury & Society Affiliate Scientists Senior Scientists Sonya Allin Mark Bayley Jennifer Boger Angela Colantonio Sven Dickinson Scientist David Fleet Nora Cullen Deborah Hébert Affiliate Scientists Dana Kulić Deirdre Dawson Alan Mackworth Emily Nalder Goldie Nejat Mary Stergiou-Kita Pascal Poupart Rosemary Ricciardelli Artificial Intelligence & Robotics for Rosalie Wang Rehabilitation Senior Scientist Brain Discovery & Recovery Alex Mihailidis Senior Scientist Scientist Robin Green Babak Taati Affiliate Scientists Asaf Gilboa Jennifer Steeves 38 Cardiorespiratory Fitness Mobility Optimization of the Rehab Senior Scientists Senior Scientists System David Alter Mark Bayley Senior Scientists Sherry Grace Dina Brooks Mark Bayley Scientists Brian Maki Cheryl Cott Tracey Colella William McIlroy Andrea Furlan Paul Oh W Darlene Reid Susan Jaglal Affiliate Scientists Scientists Pia Kontos Jack Goodman William Gage Katherine McGilton Krista Lanctôt Avril Mansfield I Gary Naglie Walter Swardfager Kara Patterson Scientists Scott Thomas Affiliate Scientists Shabbir Alibhai Alastair Flint Nora Cullen Communication Mary Fox Affiliate Scientists Senior Scientists Jesse Hoey G Ross Baker Elizabeth Rochon Andrea Iaboni Veronique Boscart Yana Yunusova Elizabeth Inness Jill Cameron Scientist Andrew Laing Mary Fox Frank Rudzicz Sunita Mathur Nancy Salbach Affiliate Scientists Laura Middleton Kathryn Sibley Melanie Baljko George Mochizuki Boaz Ben-David Stephen Perry Sleep Science Craig Chambers James Pratt Senior Scientists Tom Chau Luc Tremblay T Douglas Bradley Petros Faloutsos Karl Zabjek W Darlene Reid Julie Mendelson Scientists Aravind Namasivayam Neural Engineering & Hisham Alshaer Frank Russo Therapeutics Azadeh Yadollahi Gurjit Singh Senior Scientists Affiliate Scientists Pascal van Lieshout B Catharine Craven Owen Lyons Milos Popovic Clodagh Ryan Home, Community & Scientists Institutional Environments César Márquez-Chin Swallowing Science Senior Scientists Kei Masani Senior Scientist Geoff Fernie Kristin Musselman Catriona Steele Andrea Furlan Jose Zariffa Affiliate Scientist Scientists Affiliate Scientists Lisa Duizer Jennifer Campos Sandra Black Tilak Dutta Julio Furlan Clinical Researchers Bruce Haycock Lora Giangregorio Julia Alleyne Behrang Keshavarz Sander Hitzig Anthony Burns Alison Novak Pamela Houghton Ann Heesters Christine Novak Ethne Nussbaum Susan Marzolini Affiliate Scientists Linda Rapson Colleen McGillivray Veronique Boscart Molly Verrier Denyse Richardson Karen Gordon Timothy Welsh Gaétan Tardif Dinesh Kumbhare Paul Yoo Matthew Muller Hani Naguib Donald Philip Veronica Wadey

39 Research Committees

Biomedical Samantha Sonshine Marcia Flynn-Post Clinical Studies Research Ethics Lorisa Stein Jasmine Grant Quality Committee Board: Panel A Naomi Visanji Julie Gundry Lisa Alcia Alan Barolet (Chair) Hannah Walters-Vida Sisi Jia Charles Chan Sharon Braganza Tuula Kalliomäki (Co-Chair) Kim Cadario Cancer Clinical Jennifer Li Jordan Feld Derek Cathcart Research Unit Karen Ng John Floras Robert Cusimano Executive Gerard Paras Carole Garmaise Seema David Committee Nishita Parekh John Granton Erin Dobbelsteyn James Brierley Michele Petrovic Ann Heesters James Downar Pamela Degendorfer (Interim) Jin Huh Nicole Feldman (Co-Chair) Jesus Piza-Rodriguez Deepali Kumar Scott Fung Penelope Bradbury Tracey Powell Paul MacPherson Peter Giacobbe Anthony Fyles Menaka Pulandiran Paul Oh Andrew Ha Krystal Internicola Kendra Ross Amit Oza Matt Kim (ex officio) Maria Schlag Patrik Rogalla Jane Lui Breffni Hannon Susanna Sellmann Katie Roposa Connie Marras Jennifer Knox (Co-Chair) David Urbach (Vice Chair) Amit Oza (Chair) Vanessa Speers Sharon Walmsley Heather Sampson Michael Reedijk Marissa Tang Fong Bradly Wouters Carl Virtanen Patrik Rogalla Ruth Turner (Co-Chair) Jean Wang Pam Savage Smitha Udagani Duminda Wijeysundera Aaron Schimmer (Interim) Data Safety Noe Zamel Susanna Sellmann Celeste Yu Monitoring Board Theo van der Kwast Mary Anne Chappell Biomedical Cancer Registry Heather Cole (ex officio) Research Ethics Cancer Clinical and Data Access Kathy Han Board: Panel B Research Unit Committee Krystal Internicola Ian Arnold Management Niki Agelastos (ex officio) Alan Barolet (Chair) Committee (Committee Haiyan Jiang Ruth Anne Baron Rose Belcastro Secretariat) Girish Kulkarni David Barth Melanie Berger Penny Bradbury John Kuruvilla (Vice Chair) Chantale Blattler James Brierley (Chair) Srikala Sridhar (Chair) Daniel Buchman Cynthia Bocaya Carol Cheung Ruth Turner David Cherney (Interim) Darlene Dale Natasha Danson Karen Chadwick (Co-Chair) Krembil Nigil Haroon Bholy Chaudhary Alexandra Easson Appointments Magdy Hassouna Helen Chow (Interim) Calven Eggert Committee Michael Hutcheon Heather Cole David Goldstein Aileen Davis Ali Naraghi Pamela Degendorfer Joelle Helou Peter Carlen John Parker (Chair) John Kuruvilla Karen Davis Ron Seto Anna Dodd Tony Panzarella James Eubanks Morris Sherman Jeff Doi Bayardo Perez- Andres Lozano (Chair) Ordonez Valerie Wallace 40 Donald Weaver Krembil Clinician Manoj Vasudeva Gilbert Privé Rehabilitation Investigator Julie Wan Gary Rodin Medicine and Appointments Joan Wither Robert Rottapel Science Research Committee Meital Yerushalmi Vuk Stambolic Ethics Board: Panel D Mary Pat McAndrews Puja Ahluwalia Y Raja Rampersaud Oncology Research PM Equipment Tania Artinian Antonio Strafella Ethics Board: Panel C Committee Jeffery Baine Donald Weaver (Chair) Eitan Amir (Vice Chair) Laurie Ailles Carly Barbon Jennifer Bell Mitsuhiko Ikura Ahmed Bilal Krembil Space Hal Berman Rama Khokha Jennifer Boger Committee Marcus Butler Thomas Kislinger Anthony Burns Aileen Davis Michael Crump Trevor Pugh Tracey Colella Karen Davis Stephanie DeLuca Robert Rottapel Carol Fancott James Eubanks (Chair) Robert Dinniwell Malcolm Smith Heather Flett Ian McDermott Master Donald Ming-Sound Tsao Igor Gontcharov Frank Vidic Jaime Escallon Brian Wilson (Chair) Ann Heesters (Chair) Valerie Wallace Ronald Feld Patrick Yau Shadi Katirai Donald Weaver Eli Fellman Pia Kontos Joan Wither Anthony Fyles PM Space Avril Mansfield Robert Hamilton Committee César Márquez Chin Krembil Trainee Aaron Hansen Michael Hoffman Kei Masani Affairs Committee Jack Holland (Chair) Mitsuhiko Ikura Nadia Meli Anna Badner Belling Leung Rama Khokha Sonia Minasian Jason Charish Carmen Li Pamela Ohashi (Chair) Ashwini Namasivayam Jonathon Chio Manjula Maganti Gary Rodin Diane Nixon Leanne DaCosta Caroline McNamara Aaron Schimmer Stephanie Nixon Aidan Dineen Frank Michelis Paul Oh (Vice Chair) Rachel Dragas Rebecca Prince Radionuclide Safety Archna Patel Helal Endisha Nikolina Radulovich Committee Linda Penoyer Nisah Ganeswaren Albiruni Razak Shelley Belford Marta Pesin Alexandre Guet- Katherine Renison Jonathan Brotchie Karen Sasaki McCreight Gordon Robinson Gina Capone Catriona Steele Peter Hung Gregory St. Pierre Perry Chong Yervant Terzian William Hutchison Jenna Sykes Mary Fountas Daniel Vena Amy Ma Santhosh Thyagu Judy Gabrys Rosalie Wang Mary Pat McAndrews Ruth Turner (Co-Chair) Rosalind Waxman Carley McPherson Mihaela Ginj Nykema Wright Samira Patel PM Appointments David Green Lesley Wylie Kaitlyn Price Committee Norman Iscove Emma Reble Razqallah Hakem Ian McDermott Cricia Rinchon Richard Hill Ur Metser Anton Rogachov Norman Iscove Jerry Plastino Kairavi Shah David Jaffray Deborah Scollard Frances Skinner (Chair) Rama Khokha (Chair) Frank Tourneur Alessandra Tuccitto Tak Mak (Co-Chair) Uilki Tufa Mark Minden Li Zhang

41 Research Committees

Research Biosafety TGHRI TRI Junior TRI Team Leaders’ Committee Appointments Scientists’ Support Committee Lorraine Kalia Committee & Mentorship Mark Bayley Carly Rebelo David Cherney Committee Angela Colantonio Jeanette MacLean Angela Cheung Tracey Colella B Catharine Craven (ex officio) Myron Cybulsky Susan Jaglal (Chair) Tilak Dutta Ian McDermott Murray Krahn Avril Mansfield Geoff Fernie (Chair) (ex officio) Anna Gagliardi Lois Ward Robin Green Badru Moloo (ex officio) Margaret Herridge Azadeh Yadollahi Catharine Hancharek Gilbert Privé Mansoor Husain (ex officio) John Shannon Robert Nolan TRI Scientists’ Susan Jaglal (Acting Chair) Brad Wouters Productivity Owen Lyons Jason Fish & Promotions Katherine McGilton Research Risk and Thomas Waddell Committee Alex Mihailidis Audit Committee (Chair) Geoff Fernie Paul Oh Lisa Alcia (Chair) Minna Woo Susan Jaglal Milos Popovic Chip Campbell Milos Popovic (Chair) Catriona Steele Gabriella Fischer TRI Central Yana Yunusova Tom Goldthorpe Patient & Subject TRI Standard Tony Goncalves Recruitment Operating TRI Leadership Alex Karabanow Committee Procedures Committee Sandra Karlovich Mark Bayley Committee Geoff Fernie Anthony Palma B Catharine Craven Jennifer Campos Susan Jaglal Amy Ma (Chair) Geoff Fernie Milos Popovic (Chair) Paul MacPherson Geoff Fernie (Co-Chair) Carley McPherson Susan Jaglal Catharine Hancharek Ian McDermott Simon Jones Susan Jaglal Peggy McGill Katherine McGilton Kathy McGilton TRI International (Co-Chair) Tracy McQuire Scientific Advisory Milos Popovic Arjeta Meneri Committee Lois Ward Badru Moloo Martin Ferguson-Pell Lisa Murphy William Mann TRI Students’ Katie Roposa Anne Martin-Matthews Support & (Co-Chair) (Chair) Mentorship Evelina Rutkowski Alain Ptito Committee Gianfranco Scipione Jerker Rönnberg Susan Jaglal (Chair) Anita Sengar John Steeves Lois Ward John Shannon Nisha Ganeswaren Mike Voth Lois Ward Bradly Wouters Patrick Yau

42 External Sponsors Our partners provide key support for our research activities

Abbott American Society of Transplant Brain & Behavior Research AbbVie Surgeons Foundation Acetylon Pharmaceuticals American Society of Brain Canada Acorda Therapeutics Transplantation BresoTEC Actelion Pharmaceuticals American Thoracic Society Bristol-Myers Squibb ActiveO Amgen British Columbia Cancer Acumyn Anesthesia Patient Safety Agency Adamas Pharmaceuticals Foundation Canada Foundation for Adaptimmune AOSpine Innovation Aeglea Biotherapeutics apceth Biopharma Canada Health Infoway Aerie Pharmaceuticals APOCARE Pharma Canada Research Chairs AGA Medical Arbor Research Collaborative Canadian Agency for Drugs and Agensys for Health Technologies in Health AGE-WELL Arbutus Biopharma Canadian Allergy, Asthma and Agios Pharmaceuticals Arthritis Research Foundation Immunology Foundation Alcon Canada Associated Medical Services Canadian Anesthesiologists’ Alexion Pharmaceuticals Association of University Society Alfred Health Radiologists Canadian Arthritis Network Alion Pharmaceuticals Astellas Pharma Canadian Association for the Allergan Astex Pharmaceuticals Study of the Liver AllerGen AstraZeneca Canadian Association of Alnylam Pharmaceuticals Avanir Pharmaceutical Psychosocial Oncology Alpha Cancer Technologies Barbara Ann Karmanos Cancer Canadian Association of Alzheimer Society of Canada Institute Radiation Oncology Alzheimer’s Association Bard Canada Canadian Blood and Marrow American Academy of Bavarian Nordic Transplant Group Otolaryngology Baxter Canadian Blood Services American Association for Bayer Canadian Breast Cancer Cancer Research Beckman Coulter Foundation American Association for Benvenue Medical Canadian Cancer Society Thoracic Surgery Beth Israel Deaconess Medical Research Institute American Association of Center Canadian Diabetes Association Neurological Surgeons Bill & Melinda Gates Canadian Foundation for AIDS American College of Radiology Foundation Research Imaging Network BioCanRx Canadian Frailty Network American College of Biocompatibles UK Canadian Heart Research Centre Rheumatology Biogen Canadian Hematology Society American Society of Biosensors International Canadian Institutes of Health Hematology Boehringer Ingelheim Research American Society of Boston Biomedical Canadian Liver Foundation Nephrology Boston Children’s Hospital Canadian National Transplant American Society of Boston Medical Center Research Program Neuroradiology Boston Scientific Canadian Occupational Therapy Foundation

43 External Sponsors

Canadian Partnership Against CReATe Cord Blood & Peristem Hamilton Health Sciences Cancer Cell Bank Hauptman-Woodward Medical Canadian Partnership for Stroke CSL Behring Research Institute Recovery CTI BioPharma Health Technology Exchange Canadian Patient Safety Institute Cystic Fibrosis Canada Heart and Stroke Foundation of Canadian Psychological Daiichi Sankyo Canada Association Dartmouth College Heart and Stroke Foundation of Canadian Pulmonary Fibrosis Department of National Defence Ontario Foundation DLVR Therapeutics Hemostemix Canadian Radiation Oncology DNAtrix Henry Ford Health System Foundation Duke University Hôpital Maisonneuve-Rosemont Canadian Rheumatology Dystonia Medical Research Horizon Pharma Association Foundation Hospira Canadian Society of Hospital Edwards Lifesciences Hybridyne Imaging Pharmacists Elekta Technologies Canadian Urological Association Eli Lilly Canada Icahn School of Medicine at Cancer Care Ontario EMD Group Mount Sinai Cancer Research Institute Emory University Imago BioSciences Cancer Research Society Epilepsy Canada Immune Diagnostics & Research CannScience Innovations Epizyme ImmunoCellular Therapeutics Carestream Health Essilor INC Research Caris Life Sciences European Organisation for Inception Sciences CASI Pharmaceuticals Research and Treatment of INSIGHTEC Cedars-Sinai Medical Center Cancer Insmed Celgene Exact Imaging Institut de recherche Robert- Celsion Exelixis Sauvé en santé et en securité Centre for Addiction and Mental FedDev Ontario du travail Health Ferring Pharmaceuticals Institut universitaire de Centre for Commercialization of Fluidigm cardiologie et de pneumologie Regenerative Medicine Foundation Fighting Blindness de Québec Centre hospitalier de Fred Hutchinson Cancer Institute for Clinical Evaluative l’Université de Montréal Research Center Sciences Cervical Spine Research Society Fresenius Kabi Intercept Pharmaceuticals Children’s Hospital of Eastern Friends of FACES InterMune Ontario GBS/CIDP Foundation International Human Frontier Children’s Hospital of International Science Program Philadelphia GE Canada International Parkinson and Chimerix Genentech Movement Disorders Society CIHR Canadian HIV Trials Genome Canada International Rett Syndrome Network Genzyme Foundation Cincinnati Children’s Hospital George Institute for Global International Society for Heart Medical Center Health & Lung Transplantation Cleave Biosciences Gilead Sciences International Society for Clinique La Prairie Glaucoma Research Society of Peritoneal Dialysis Colon Cancer Canada Canada Interrad Medical Columbia University GlaxoSmithKline InVivo Therapeutics Concordia Pharmaceuticals Global Affairs Canada IQVIA Conkwest Grand Challenges Canada iRT Systems Conquer Paralysis Now Grifols Israel Cancer Research Fund Cook Group Hackensack University Medical J.P. Bickell Foundation Craig H. Neilsen Foundation Center Jaeb Center for Health Research

44 Janssen Microbot Medical Ontario HIV Treatment Jewish General Hospital Ministry of Education Network Johns Hopkins University Ministry of Health and Long- Ontario Institute for Cancer Johnson & Johnson Term Care Research JSS Medical Research Ministry of Labour Ontario Institute for Juvenile Diabetes Research Ministry of Research, Regenerative Medicine Foundation Innovation and Science Ontario Lung Association Karyopharm Therapeutics Mitacs Ontario Mental Health Kiadis Pharma MolecuLight Foundation Kidney Cancer Canada Morton Cure Paralysis Fund Ontario Neurotrauma Kidney Foundation of Canada Mount Sinai Hospital Foundation Krembil Foundation Multiple Myeloma Research Ontario Stroke Network Kyowa Hakko Kirin Foundation Ontario Telemedicine Network Lawson Health Research Multiple Sclerosis Society of Ontario Thoracic Society Institute Canada Onyx Pharmaceuticals Leidos Biomedical Research Muscular Dystrophy Canada Ophthotech Leukemia and Lymphoma Myeloma Canada Otsuka Canada Pharmaceutical Society National Institutes of Health Ottawa Hospital Research Leukemia and Lymphoma National Multiple Sclerosis Institute Society of Canada Society Oxford Immunotec Leukemia Research Foundation National Research Council Panacea Global of Canada Natural Sciences and Pancreatic Cancer Canada Li Ka Shing Foundation Engineering Research Council Paralyzed Veterans of America LifeLabs of Canada Education Foundation Llewellyn Market Research Nestec PAREXEL London Health Sciences Centre Netherlands Cancer Institute Parkinson Canada Lundbeck Canada Networks of Centres of Parkinson’s UK Lung Biotechnology Excellence Partners HealthCare Lupus Foundation of America NeuroDevNet Perimeter Medical Imaging Lupus Ontario New England Research Petro-Canada Lubricants Lupus Research Alliance Institutes Pfizer Lutonix New York University Pharmaceutical Product Mallinckrodt Pharmaceuticals Northern Biologics Development March of Dimes Northwestern University PharmaNet MaRS Innovation Notable Labs Philips Massachusetts General Hospital Nova Scotia Health Authority Phonak Matrizyme Pharma NOVADAQ Technologies Photopharmica Mayo Clinic Novartis Physicians’ Services McGill University Novo Nordisk Incorporated Foundation McGuire Research Institute NPS Pharmaceuticals Physiotherapy Foundation of McMaster University NRG Oncology Canada Medical Council of Canada NSABP Foundation Pierre Fabre Medical Decision Modeling Nucleix PKD Foundation MedImmune Octapharma Polynoma Medivir Olympus Population Health Research Medtronic Onconova Therapeutics Institute Merck & Co. Onkocellular PRA Health Sciences Merrimack Pharmaceuticals Ontario Brain Institute Progenics Pharmaceuticals Merz Pharma Ontario Centres of Excellence Promedior Mesothelioma Applied Research Ontario Clinical Oncology Prometic Life Sciences Foundation Group Promobilia Foundation

45 Prostate Cancer Canada St. Michael’s Hospital Triphase Accelerator Corporation Protagen Stanley Medical Research Institute UCB ProteoMediX State University of New York United States Department of Proteon Therapeutics Stemline Therapeutics Defense Prothena Stryker University Hospital Tuebingen Providence Health Care Sunnybrook Health Sciences University of Alberta Public Health Agency of Canada Centre University of British Columbia PuraPharm Sunovion University of Calgary Queen’s University Susan G. Komen University of California, Los Radiological Society of North Takara Bio Angeles America Takeda Oncology University of California, San Raysearch Laboratories TauRx Therapeutics Diego Regulus Therapeutics TD Bank Group University of California, San Revalesio Ted Rogers Centre for Heart Francisco Rick Hansen Foundation Research University of Chicago Rick Hansen Institute Terry Fox Research Institute University of Colorado Roche Terumo University of Florida Royal College of Physicians and Tesaro University of Iowa Surgeons of Canada Thalassemia Foundation of University of Louisville Saint Elizabeth Health Care Canada University of Manitoba Samuel Waxman Cancer Research The Arthritis Society University of Maryland Foundation The Arthritis Society University of Medicine and Sandra Rotman Centre The MAYDAY Fund Dentistry of New Jersey Sanofi The Michael J. Fox Foundation University of Miami Sarcoma Cancer Foundation of for Parkinson’s Research University of Michigan Canada The Parkinson’s Foundation University of Ottawa Savoy Foundation The Plastic Surgery Foundation University of Pennsylvania Schering-Plough The Princess Margaret Cancer University of Regina Seattle Children’s Hospital Foundation University of Rochester Sequana Medical The Vitamin D Society University of Saskatchewan Shionogi The W. Garfield Weston University of Texas Shire Foundation University of Toronto SickKids Theralase University of Virginia Siemens Therapure Biopharma University of Washington Sigma Theta Tau International Thoratec University of Waterloo Simon Fraser University Thornhill Medical University of Western Ontario Smiths Medical Thrasos Innovation University of Zurich Society for Vascular Surgery Threshold Pharmaceuticals Urology Association of Portugal Society of American Thrombosis Research Institute Vancouver Coastal Health Gastrointestinal and Endoscopic Tocagen Research Institute Surgeons Tokai Pharmaceuticals Veran Medical Technologies Society of Anesthesia and Sleep Tornado Spectral Systems Vernacare Canada Medicine Toronto Central Local Health Vertex Pharmaceuticals Society of Uroradiology Integration Network Virginia Commonwealth Southlake Regional Health Centre Toronto Dementia Research University SpectraCure Alliance Wake Forest University Spencer Foundation Toronto General & Western Wings for Life Spring Bank Pharmaceuticals Hospital Foundation Women’s College Hospital St. Joseph’s Healthcare Hamilton Toronto Rehab Foundation St. Jude Medical Toshiba Medical Systems St. Mary’s Research Centre Trillium Therapeutics

46 Financials Research funding by source

National Institutes of Health $9,533,414 Tri-Council Agencies $47,390,888

Canada First Research Excellence Fund $3,562,169 Industry $48,200,073 Canada Foundation for Innovation / Ministry of Research, Innovation and Science, Ontario Research Fund Infrastructure $21,640,614

Toronto General & Western Hospital Foundation* Other Nonprofit $57,642,123 Organizations $56,427,591

Toronto Rehab Foundation* Ontario Institute for Cancer $3,767,587 Research $5,644,359

Other Funding Sources $33,607,257 The Princess Margaret Cancer Foundation* $87,064,370 Canadian Cancer Society Government of Ontario Research Institute $4,911,932 $6,799,876

TOTAL FUNDING $386,192,252

Financial data provided by UHN Research Financial Services. The above figures represent funding revenues (by source) received to support direct and indirect research for the fiscal year ending March 31, 2017. The ‘Government of Ontario’ funding category represents contributions from provincial government programs, including the Ministry of Health and Long-Term Care, and the Ministry of Research, Innovation and Science (excluding the Ontario Research Fund Research Infrastructure Fund). Funding agencies/organizations that contributed $3,500,000 or more are indicated.

*The Foundations donate to UHN for purposes in addition to supporting research. As per UHN’s audited financial statements for the fiscal year ended March 31, 2017, grants and donations for research and other purposes provided by UHN foundations were: $102,460,000 for The Princess Margaret Cancer Foundation; $5,683,000 for the Toronto Rehab Foundation; and $76,777,000 for the Toronto General & Western Hospital Foundation.

47 International Research Advisory Board Samuel Weiss, PhD (Chair) Professor, Departments of Cell Biology & Anatomy and Physiology & Pharmacology, University of Calgary; Inaugural Director of the Hotchkiss Brain Institute

Philip E Branton, OC, PhD, FRSC Gilman Cheney Professor, Departments of Biochemistry and Oncology and the Goodman Cancer Centre, McGill University

Thomas Rockwell Mackie, PhD Professor Emeritus, Medical Physics and Human Oncology, University of Wisconsin; Director, Medical Devices Focus Area, Morgridge Institute for Research

Lynne Warner Stevenson, MD Director, Cardiomyopathy and Heart Failure Program, Brigham and Women’s Hospital; Professor, Harvard Medical School

John E Wennberg, MD, MPH Active Professor Emeritus of Community & Family Medicine, Peggy Y Thomson Professor Emeritus in Evaluative Clinical Sciences and Director Emeritus and Founder, The Dartmouth Institute for Health Policy & Clinical Practice Research Committee Board of Trustees Independent Trustees (Voting) Lawrence Pentland (Chair), Barbara Stymiest, Trevor Young

Ex-officio Trustees (Voting) Charlie Chan (Interim CEO), Joy Richards

Others (Voting) Sean Boyd, Tom Ehrlich, Mark Krembil, John O’Grady

Ex-officio Non-Trustees (Non-voting) Larry Baldachin, Darlene Dasent, John Granton, Bradly Wouters

Disclaimers Publications, Personnel, Research Committees: Publication data provided by UHN Research Program Planning & Analysis. Leadership data provided by UHN institute Business Managers. Data accurate as of September 1, 2017. Some figures may be rounded and/or may include data not represented in institute data. Publications jointly authored by investigators at multiple UHN institutes are counted only once in the UHN total. Researchers with more than one affiliation within an institute, or between institutes, are only included once in the total count. Metrics for each institute were calculated by considering data on all Researchers, which include CCRU or Clinical Researchers as applicable. Please note that Clinical Researchers and CCRU investigators are not formally appointed at the research institutes and are therefore not subject to the research institutes’ scientific and performance reviews. Clinical Researchers are defined as UHN staff who are listed as corresponding or principal author on at least one publication in the 2016 calendar year and/or held research funding over the 2016/17 fiscal year. †Dr. Martin Steinbach (p. 30) passed away on June 24, 2017. Trainees: Institute trainee counts are accurate as of August 1, 2017 and were provided by UHN’s Office of Research Trainees. Counts reflect trainees supervised by researchers with a primary UHN research appointment and who spent more than 50% of their time at UHN. Space: Data provided by UHN Research Facilities Planning & Safety and based on space audited by September 1, 2017 across UHN sites. Core facilities and Research Solutions and Services spaces are not included in institute space totals. Production Credits: This report is published by the Office of the Executive Vice President, Science and Research, UHN. Graphic design, writing and production by UHN’s Strategic Research Initiatives Development Team (StRIDe). Institute Financials: The ‘External Funding’ value in each snapshot represents total research project funding received by investigators that are primarily affiliated with each specific institute in the 2016/17 fiscal year.

48

Research Report

Innovation fuels our drive to make health care better, faster and stronger.

To learn more visit UHNresearch.ca

University Health Network University Health

University Health Network Research Report 2017 | Office of the Executive Vice President, Science and Research. 200 Elizabeth Street, R. Fraser Elliott, 1-S-407, Toronto, Ontario, Canada

@UHNresearchnews @UHN_Research